Shares of Diaceutics PLC (LON:DXRX – Get Free Report) hit a new 52-week high during trading on Thursday . The company traded as high as GBX 176.25 and last traded at GBX 172, with a volume of 512286 shares traded. The stock had previously closed at GBX 166.
Wall Street Analyst Weigh In
Separately, Shore Capital raised their price objective on shares of Diaceutics from GBX 180 to GBX 215 and gave the stock a “buy” rating in a research note on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of GBX 193.33.
View Our Latest Stock Report on Diaceutics
Diaceutics Trading Up 3.6%
Diaceutics Company Profile
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.
See Also
- Five stocks we like better than Diaceutics
- Trump’s AI Secret: 100X Faster Than Nvidia
- The Crash Has Already Started (Most Just Don’t See It Yet)
- Wall Street Alert: Buy AES
- New gold price target
- Trump Planning to Use Public Law 63-43: Prepare Now
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
